top of page
Shore_edited_edited_edited.jpg
Search

Amplifying Patient Voices: NCF Collaborates on Important Neuroendocrine Carcinoma Research

3 days ago
3 min read

The VOICE Study sheds light on  the experiences, challenges, and unmet needs of patients, care partners, and healthcare providers navigating extrapulmonary neuroendocrine carcinoma (epNEC), meaning neuroendocrine carcinoma that outside the lungs.


The Neuroendocrine Cancer Foundation (NCF) is proud to have collaborated on the VOICE Study, the largest to date to focus on the real-world experiences of people affected by extrapulmonary neuroendocrine carcinoma (epNEC), a rare and aggressive form of cancer.



Presented at the 2026 European Society for Medical Oncology (ESMO) Congress and the 2026 North American Neuroendocrine Tumor Society (NANETS) Symposium, two leading international medical & scientific neuroendocrine cancer conferences), the research highlights important challenges in diagnosis, treatment, access to care, and quality of life.


Understanding the Patient Journey


The VOICE Study surveyed 226 patients across the United States, providing valuable insights into their experiences living with epNEC.


Key findings included:

  • Delays in seeking care: 54% waited more than a month after symptoms began before seeking medical attention.

  • Impact on quality of life: Patients reported an average 60% impairment in daily activities and 63% work impairment among employed participants.

  • Interest in personalized treatment: While 66% had undergone biomarker testing, 94% were willing to undergo biomarker testing to help guide treatment decisions.

  • Barriers to care: More than 65% traveled at least 30 minutes each way for medical appointments, and 23% experienced treatment delays due to transportation challenges.


Patients also identified a need for greater access to specialists and novel therapies,  additional treatment options, more comprehensive educational resources, and a greater role in decision-making.


Recognizing the Role of Care Partners


The study also surveyed 102 care partners, recognizing the important role family members and caregivers play throughout the cancer journey.

Findings revealed that care partners experienced significant emotional, physical, and work-related challenges. On average, care partners reported 51% impairment in daily activities, while employed care partners experienced 58% work impairment.


These findings highlight the importance of providing education, emotional support, and practical resources not only for patients but also for those caring for them.


Insights from Healthcare Providers


A third survey gathered perspectives from 100 healthcare providers involved in managing epNEC.

The findings identified ongoing challenges in timely diagnosis, specialist referrals, treatment decisions, and access to appropriate care.


Among the participating providers, 75% reported experiencing referral delays at least occasionally, while 90% reported diagnostic challenges.


These findings underscore the need for improved awareness, earlier diagnosis, and greater access to specialized care and emerging treatment approaches.


Collaboration to Advance NEC Care


The VOICE Study brought together medical experts, patient advocates, and industry partners united by a shared commitment to improving care for the NEC community.


Dr. Aman Chauhan and Lisa Yen, Director of Programs of NCF, at the 2026 North American Neuroendocrine Tumor Society (NANETS) Symposium.
Dr. Aman Chauhan and Lisa Yen, Director of Programs of NCF, at the 2026 North American Neuroendocrine Tumor Society (NANETS) Symposium.

Collaborators included Dr. Aman Chauhan of UCSF and Dr. Jason Starr of Mayo Clinic,  along with patient advocacy organizations Minkhaz NETs Mission, Healing NETs, NCAN, NETRF, and NCF. The research was funded by Boehringer Ingelheim.


Lisa Yen, NCF's Director of Programs & Outreach, participated in this collaborative effort and had the opportunity to present one of the research posters at the 2026 NANETS Symposium in Las Vegas.


Turning Research Into Meaningful Change

The VOICE Study reinforces the importance of listening to the people most directly affected by epNEC: patients, care partners, and healthcare providers. Their experiences provide valuable insights into the challenges of living with and managing epNEC.


While the findings reflect the experiences of survey participants and may not represent everyone affected by epNEC, they highlight important opportunities to improve education, access to care, treatment decision-making, and support throughout the cancer journey.


NCF is grateful to everyone who shared their experiences and contributed to this groundbreaking research. We are also proud to collaborate with the medical and advocacy communities to ensure that patient and care partner perspectives remain an integral part of advancing research and improving care.


Together, we can amplify the voices of the NEC community and help turn their experiences into meaningful progress in research, education, and patient care.


Learn more about neuroendocrine cancer and explore resources at www.NCF.net.




 THANKS TO OUR SPONSORS






 
 
NEUROENDOCRINE CANCER FOUNDATION
 
Mailing Address:
PO BOX 370466
DENVER, CO 80237

info@ncf.net
​
  • Facebook
  • Instagram
  • X
  • Youtube
  • LinkedIn

© 2026 by Neuroendocrine Cancer Foundation

bottom of page